Gain Therapeutics
Biotechnology, 4800 Hampden Ln Ste 200, Bethesda, Maryland, 20814, United States, 11-50 Employees
Phone Number: 30********
Who is GAIN THERAPEUTICS
Gain Therapeutics is a biotechnology company focused on developing new medicines for protein misfolding diseases. Their supercomputer-driven target-based drug discovery platform, SEE-TxTM...
Read More
- Headquarters: 4800 Hampden Ln Ste 200, Bethesda, Maryland, 20814, United States
- Date Founded: 2017
- Employees: 11-50
- Revenue: $1 Million to $5 Million
- Active Tech Stack: See technologies
- CEO: Matthias Alder
Industry: Biotechnology
SIC Code: 2836 | NAICS Code: 541714 | Show More
Does something look wrong? Fix it. | View contact records from GAIN THERAPEUTICS
Gain Therapeutics Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Gain Therapeutics
Answer: Gain Therapeutics's headquarters are located at 4800 Hampden Ln Ste 200, Bethesda, Maryland, 20814, United States
Answer: Gain Therapeutics's phone number is 30********
Answer: Gain Therapeutics's official website is https://gaintherapeutics.com
Answer: Gain Therapeutics's revenue is $1 Million to $5 Million
Answer: Gain Therapeutics's SIC: 2836
Answer: Gain Therapeutics's NAICS: 541714
Answer: Gain Therapeutics has 11-50 employees
Answer: Gain Therapeutics is in Biotechnology
Answer: Gain Therapeutics contact info: Phone number: 30******** Website: https://gaintherapeutics.com
Answer: Gain Therapeutics is a biotechnology company focused on developing new medicines for protein misfolding diseases. Their supercomputer-driven target-based drug discovery platform, SEE-TxTM, is a novel approach that uses structural and computational biology to discover previously unidentified allosteric binding sites with high potential for druggability. These sites can be targeted with small molecules for therapeutic benefit to correct enzyme misfolding, thereby restoring function, eliminating toxic substrate, and addressing the underlying cause of disease. SEE-TxTM is an entirely new drug discovery and development process made possible by Supercomputing with the potential to transform this process into a more efficient method with life changing treatments created in a fraction of the time at a fraction of the cost and for multiple disease target. The platform has generated all of the development candidates currently in Gains pipeline. Gain has an initial focus in lysosomal storage diseases and CNS disorders, but the platform is agnostic and can be applied to any disease caused by protein misfolding, including the disease areas of metabolism, immunology, and oncology. The company has an experienced and highly successful Board of Directors and management team with over $30 billion in transactional history.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month